Codexis is a biosciences company applying synthetic chemistry technologies to create improved versions of small molecule therapeutics.
Codexis, Inc. is an industrial biotechnology company that specializes in engineers enzymes for pharmaceutical and chemical production through biocatalysis. Codexis’ technologies enable scale-up and implementation of biocatalytic solutions to optimize process development, from research to manufacturing. There are currently over 50 pharmaceutical firms using Codexis’ technology, products and services in their manufacturing process development.Codexis creates its products by applying its CodeEvolver® directed evolution technology platform, which introduces genetic mutations into microorganisms.Codexis, Inc. began operations as an independent company in 2002, and became a publicly traded company in 2009. They are located in Redwood City, CA USA
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 2, 2020 | Post-IPO Equity | $75M | — | — | — | Detail |
Jun 20, 2019 | Post-IPO Equity | $50M | 1 | Casdin Capital | — | Detail |
Apr 30, 2010 | IPO | $78M | — | — | — | Detail |
Aug 14, 2006 | Series D | $37M | 5 | EDBI | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Mar 29, 2022
seqWell
|
Series C | $7M | Biotechnology | Yes |
Mar 15, 2022
Molecular Assemblies
|
Series B | $25.80M | Biotechnology | — |
Apr 15, 2021
Molecular Assemblies
|
Series A | $11.80M | Biotechnology | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Casdin Capital | Yes | Post-IPO Equity |
EDBI | Yes | Series D |
Chevron Technology Ventures | — | Series D |
CMEA Capital | — | Series D |
Maxygen | — | Series D |
Pequot Capital | — | Series D |